Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 in Recurrent/Metastatic SCCHN
NCT04650633Phase 2Unknown
- Sponsor
- Hengrui
- Start
- May 2021
- Primary completion
- Jan 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Hengrui. Status: unknown.
02
Drugs
retlirafusp alfa
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT04650633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04650633.